Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Mar 2, 2018

FDA to review Dupixent® (dupilumab) as potential treatment for moderate-to-severe asthma
Feb 14, 2018

Toujeo® reduced risk of severe low blood sugar compared to insulin glargine 100 Units/mL and insulin detemir
- Photos 1
Feb 7, 2018

Sanofi Delivers 2017 Business EPS in line with Guidance
- Photos 5
Jan 8, 2018

Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs

Companies also announce submission of dupilumab supplemental BLA for uncontrolled, persistent asthma
Dec 13, 2017

Sanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamous cell carcinoma

High and durable response rate in disease without any FDA-approved therapies

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.